Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naloxone 2 MG Clear all
Completed Phase 1Phase 2 Interventional Results available

Medications Development for Drug Abuse Disorders

NCT01188421
View directory record Official record
Conditions
Opioid Related Disorders, Opioid Dependence, Opioid Addiction
Interventions
Buprenorphine/naloxone, Clonidine, Tramadol ER
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 7, 2026, 7:05 AM EDT
Terminated Phase 4 Interventional

Novel Induction to Buprenorphine/Naloxone

NCT05644587
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Bicycle Health
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 7, 2026, 7:05 AM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

Opioid Treatment and Recovery Through a Safe Pain Management Program

NCT03889418
View directory record Official record
Conditions
Depression, Opioid Use, Chronic Pain, Anxiety
Interventions
Electronic medical recorded clinical decision support [EMR CDS], Stepped opioid collaborative care model [CCM]
Behavioral
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 3 Interventional

Medication and Counseling for Controlled Drinking (Project SMART)

NCT00444418
View directory record Official record
Conditions
Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions
Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).

NCT01750060
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Fentanyl, Naltrexone
Drug
Lead sponsor
Incline Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 7, 2026, 7:05 AM EDT
Active, not recruiting Early Phase 1 Interventional

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

NCT04744883
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT)
Other · Drug · Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Targeted Interventions for Weight-Concerned Smokers

NCT00105482
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Naltrexone, Transdermal nicotine replacement, Behavioral counseling
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 4 Interventional Results available

Understanding Treatment Response With Naltrexone Among White Alcoholics

NCT00817089
View directory record Official record
Conditions
Alcoholism
Interventions
Placebo Oral Tablet, Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Combining Varenicline and Naltrexone for Smoking Cessation

NCT02698215
View directory record Official record
Conditions
Nicotine Dependence, Alcohol Use Disorder
Interventions
Varenicline, Varenicline plus Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 3 Interventional

Combined Pharmacotherapies for Alcoholism

NCT00768508
View directory record Official record
Conditions
Alcoholism
Interventions
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy, Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

INDV-6001 Multiple-Dose Pharmacokinetic Study

NCT06576843
View directory record Official record
Conditions
Moderate to Severe Opioid Use Disorder
Interventions
INDV-6001, Suboxone, Sublocade
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Diego, California • Miami Lakes, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction & Methadone & Buprenorphine

NCT02045693
View directory record Official record
Conditions
Hepatitis C
Interventions
Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

NCT02911597
View directory record Official record
Conditions
Depression
Interventions
Naltrexone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence

NCT01214083
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
West Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 7, 2026, 7:05 AM EDT